铂类抗肿瘤药物耐药机制的研究进展和应对策略  

Research progress and coping strategy of the drug resistant mechanism of platinum anti-tumor drugs

作　　者：王冬博 聂晶 武慧娜 孙磊 刘丽慧 吴记勇 WANG Dongbo;NIE Jing;WU Huina;SUN Lei;LIU Lihui;WU Jiyong(Department of Pharmacy,Shandong Second Provincial General Hospital,Jinan 250022,China)

机构地区：[1]山东省第二人民医院药学部,山东济南250022

出　　处：《药学实践杂志》2022年第4期302-308,共7页Journal of Pharmaceutical Practice

基　　金：山东省医药卫生科技发展计划项目(202113010614)。

摘　　要：铂类抗肿瘤药物是目前临床应用最广泛的一线化疗药物,疗效显著。但临床使用过程中出现的非小细胞肺癌、乳腺癌、卵巢癌等铂类药物耐药问题,严重影响了铂类药物的疗效,也极大限制了铂类药物的使用。铂类药物耐药是由多种因素引起的,目前关于铂类药物的耐药机制主要有以下几个方面:减少细胞内铂的积累、促进细胞内铂的失活、DNA的损伤修复能力增强、肿瘤细胞凋亡抑制作用增强等。本文就铂类抗肿瘤药物的耐药机制和应对策略做一综述,为铂类抗肿瘤药物的研发提供思路,为克服临床铂类药物耐药问题提供参考。Platinum anti-tumor drugs are currently the most widely used first-line chemotherapeutic drugs in clinical practice,and their curative effects are remarkable.However,the problems of platinum drug resistance in non-small cell lung cancer,breast cancer,ovarian cancer and others seriously limit effectiveness and clinical application of platinum drugs.The occurrence of platinum drug resistance is caused by many factors.At present,the resistance mechanism of platinum drugs mainly includes the following aspects:decreasing the accumulation of platinum in cells,increasing the inactivation of platinum in cells,repairing DNA damage and tumor cell apoptosis inactivation.This article reviews the drug resistance mechanism and coping strategy of platinum anti-tumor drugs,providing ideas for the development of platinum anti-tumor drugs and references for overcoming clinical platinum drug resistance.

关 键 词：铂类药物 抗肿瘤药物 耐药机制 

分 类 号：R979.1[医药卫生—药品]